Tag:

Sanofi

Latest Headlines

Latest Headlines

J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test

Pharma giants AstraZeneca, Johnson & Johnson and Sanofi have teamed up with gene sequencing pioneer Illumina to create a single test that screen patients for a wealth of cancer-related gene variants, allowing drugmakers to identify the ideal recipients of their oncology drugs.

Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020

The dengue vaccine market may not exist yet, but once it does, it's in for a big growth spurt within the next 6 years, a recent report says. And while market watchers expect Sanofi's candidate to lead the pack, by the time 2020 rolls around, Takeda could be right behind it in the battle for market share.

Price could be key for Sanofi's new Gaucher pill as it sets out against IV rivals

More than a couple of markets have been shaken up lately by new competition in oral form. And now, Sanofi's Genzyme is wondering if it can't make a splash of its own with Cerdelga, its newly approved pill for Gaucher disease.

Sanofi wins FDA's blessing for an oral Gaucher drug

Sanofi's rare ailment-focused Genzyme unit won FDA approval for a new Gaucher disease treatment, providing an oral alternative to its own trailblazing intravenous therapy.

Lilly, Boehringer score FDA backing for Lantus copy, but patent fight awaits

Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.

Sanofi shipping new malaria treatment manufactured from 'semisynthetic artemisinin'

French drugmaker Sanofi has released its first batches of a malaria treatment made from semisynthetic artemisinin using a new manufacturing process that will allow it to make tons of the ingredient and so help stabilize its volatile global market.

Lilly grabs a 'tentative' FDA OK for insulin treatment, but Sanofi still blocks its path

Eli Lilly has won a "tentative" FDA approval for its knockoff of Sanofi's Lantus, but don't look for it at a pharmacy anytime soon. The insulin glargine injection--to be marketed as Basaglar eventually in the U.S.--faces an automatic 30-month stay after Sanofi filed a suit against Lilly and its partner Boehringer Ingelheim claiming patent infringement.

Sanofi's high-dose Fluzone beats standard-dose version in protecting seniors

Sanofi appealed to the FDA to change the labeling of its high-dose Fluzone vaccine to reflect superior efficacy data in people aged over 65, and now it has fresh trial results to back up its case that Fluzone High-Dose provides better protection in individuals in this age group compared to traditional flu jabs.

Former top Sanofi exec Whitaker nabbed by Synta to shuttle cancer drug to market

Less than a week after mysteriously leaving a prestigious post as president of Sanofi's North American pharma unit, Anne Whitaker has tackled a rather different challenge, accepting the CEO job at Synta Pharmaceuticals, a company that has struggled to get any drugs out of its pipeline since its founding 13 years ago.

MannKind recruits Sanofi to hawk Afrezza in $925M marketing deal

MannKind has adopted an "If you can't beat 'em, join 'em" strategy for its newly approved Afrezza. Instead of going up against diabetes giants the likes of Sanofi, MannKind is joining hands with the French drugmaker in a marketing partnership worth up to $925 million.